// App-Quantinova.ai

257 : Secukinumab demonstrates a consistent safety profile with up to 5 years’ treatment in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses

Researchers

Presenter

  • Iain B McInnes

Principal Investigators

  • Philip J Mease

  • Kristian Reich

  • Peter Nash

  • Albert Widmer

  • Ken Abrams

  • Luminita Pricop

  • Todd Fox

Medical Centers

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA

  • Dermatology, Dermatologikum Berlin and SCIderm Research Institute, Hamburg, GERMANY

  • Department of Medicine, University of Queensland, St Lucia, AUSTRALIA

  • Immunology, Hepatology, and Dermatology Development Unit, Novartis Pharma AG, Basel, SWITZERLAND

  • Oncology Clinical Development, Novartis Pharmaceuticals Corporation, East Hanover, NJ

  • Immunology and Dermatology Franchise, Novartis Pharma AG, East Hanover, NJ

Locations

  • United Kingdom

  • United States

  • Germany

  • Australia

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriatic arthritis

  • Psoriasis

  • Inflammatory Arthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved